Timing is Everything: Early Chemotherapy Boosts Colorectal Cancer Survival
Study finds starting chemotherapy within 6 weeks after colorectal cancer surgery improves survival rates.
Novel combination therapy shows promise for anaplastic thyroid carcinoma, significantly improving survival.
Long-term analysis shows superior locoregional control with high-dose cisplatin in head and neck cancer.
Network meta-analysis finds no significant difference in survival between weekly and bolus cisplatin for head and neck cancer.
Meta-analysis reveals DPYD gene variants significantly increase death risk in fluoropyrimidine chemotherapy.
Study finds weekly cisplatin reduces kidney injury risk without compromising survival in head/neck cancer.
Toripalimab plus chemotherapy significantly improves survival in recurrent/metastatic nasopharyngeal carcinoma.
Study finds L-glutamine supplementation does not negatively impact survival in head and neck cancer patients